Please login to the form below
VX-880
This page shows the latest VX-880 news and features for those working in and with pharma, biotech and healthcare.
Vertex moves ahead with its bid to develop a curative treatment for type 1 diabetes
Vertex has released results from its phase 1/2 trial for VX-880, a stem-cell-derived therapy that restores insulin production. ... VX-880 is a stem-cell-derived, fully differentiated pancreatic islet cell replacement therapy that is delivered as a single
Latest news
-
Vertex gains FDA fast track designation for diabetes stem cell therapy
Vertex says VX-880 has potential to restore pancreatic islet cell function, including insulin production, in type 1 diabetes patients. ... Vertex gained VX-880 from its previous acquisition of Semma Therapeutics for $950m in September 2019.
-
Vertex eyes type 1 diabetes cure with biotech acquisition
Will acquire Semma Therapeutics for $950m
More from news
Approximately 2 fully matching, plus 1 partially matching documents found.
Latest from PMHub
-
Why you should feel optimistic about the future of healthcare
His company was bought out and recently launched a clinical trial of VX-880, a stem cell-derived beta cell therapy, in people with type 1 diabetes.
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
- Senior Medical Copywriter - Highly Awarded Advertising Agency
- £50,000 - £60,000 yearly
- Account Manager, 6 month contract, Healthcare Brand communicatio...
- Highly competitive salary
- Account Director, Healthcare Marketing Creative Agency, Fixed te...
- Highly competitive salary
- Home Based Account Manager, Medical Communications, UK, Pharma/M...
- Highly competitive salary
- Market Access Director, six figure base salary and £5K joining b...
- Highly competitive salary
- Account Manager, Healthcare Marketing Creative Agency, Fixed ter...
- Highly competitive salary
- Pfizer reports positive results for elranatamab in multiple myeloma
- BMS presents positive four-year results for Opdivo combination in lung cancer
- AstraZeneca to stop post-marketing study of Andexxa following early success
- Amgen’s Lumakras shows promise in phase 3 lung cancer study
- Novartis receives EC approval for Cosentyx in hidradenitis suppurativa
- Pfizer’s antibiotic combination shows promise in treating multi-drug resistant infections
- European Commission grants two new marketing authorisations for UCB's Bimzelx
- AstraZeneca/Sanofi’s RSV antibody backed by FDA advisory committee for infants
- Janssen shares positive phase 3 results for cilta-cel in multiple myeloma
- Parkinson’s disease: past, present and future
- How to Increase Engagement During Virtual Events
- AstraZeneca to stop post-marketing study of Andexxa following early success
No results were found
PMHub
Mednet Group
PMEA Agency of the year 2021. With diversity and inclusion at our core, Mednet Group consists of Attigo CIC and...
Latest intelligence
- Parkinson’s disease: past, present and future
- Examining the history and complexities of Parkinson’s disease – one of the most prevalent neurodegenerative disorders that affects over 10 million people worldwide...
- The 17th World Congress on Controversies in Neurology
- This year, there was a focus on the rare disease neuromyelitis optica spectrum disorder that strikes suddenly and mainly impacts women...
- Archetypes: Rethinking go-to-market expectations to drive commercial success
- In this white paper, our consultants analyze trends spanning global policy developments, rising inflation, and increasingly complex customer journeys, and reveal a new data-driven approach to archetyping that crystalizes the...
